CN115916177A - 与甲状腺激素相关的疾患的治疗 - Google Patents

与甲状腺激素相关的疾患的治疗 Download PDF

Info

Publication number
CN115916177A
CN115916177A CN202180030618.0A CN202180030618A CN115916177A CN 115916177 A CN115916177 A CN 115916177A CN 202180030618 A CN202180030618 A CN 202180030618A CN 115916177 A CN115916177 A CN 115916177A
Authority
CN
China
Prior art keywords
vitamin
thyroid hormone
folic acid
ahds
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180030618.0A
Other languages
English (en)
Chinese (zh)
Inventor
林茨·O·斯科特三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN115916177A publication Critical patent/CN115916177A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180030618.0A 2020-04-22 2021-04-22 与甲状腺激素相关的疾患的治疗 Pending CN115916177A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063013960P 2020-04-22 2020-04-22
US63/013,960 2020-04-22
US202063088523P 2020-10-07 2020-10-07
US63/088,523 2020-10-07
US202163135118P 2021-01-08 2021-01-08
US63/135,118 2021-01-08
PCT/US2021/028675 WO2021216896A1 (en) 2020-04-22 2021-04-22 Treatment of conditions associated with thyroid hormone

Publications (1)

Publication Number Publication Date
CN115916177A true CN115916177A (zh) 2023-04-04

Family

ID=78270024

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180030618.0A Pending CN115916177A (zh) 2020-04-22 2021-04-22 与甲状腺激素相关的疾患的治疗

Country Status (12)

Country Link
US (1) US20230149410A1 (enExample)
EP (1) EP4138809A4 (enExample)
JP (1) JP2023522956A (enExample)
KR (1) KR20230015906A (enExample)
CN (1) CN115916177A (enExample)
AU (1) AU2021260956A1 (enExample)
BR (1) BR112022021420A2 (enExample)
CA (1) CA3175608A1 (enExample)
IL (1) IL297453A (enExample)
MX (1) MX2022013140A (enExample)
PH (1) PH12022553118A1 (enExample)
WO (1) WO2021216896A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121910745A (zh) * 2026-03-23 2026-04-24 暨南大学 N-乙酰神经氨酸在制备治疗甲基苯丙胺成瘾的药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522112A (ja) * 2022-07-11 2025-07-10 プリズム・エルエルシー アラン・ハーンドン・ダドリー症候群を治療するための方法
CA3261855A1 (en) * 2022-07-11 2024-01-18 PriZm, LLC METHODS AND FORMULATIONS OF GENE THERAPY, AND OF COMBINATION OF GENE THERAPY WITH DITPA THERAPY, FOR ALLAN-HERNDON-DUDLEY SYNDROME
US20240350591A1 (en) * 2023-04-12 2024-10-24 Xygenyx Inc. Composition and methods of treatment using synergistically-enhanced supplementation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030352A1 (en) * 1999-10-28 2001-05-03 Cary Pharmaceuticals Inc. High dose folic acid for the treatment of hyperhomocysteinemia
US20110008464A1 (en) * 2009-07-10 2011-01-13 Scott Iii Linzy O Methods and compositions for treating thyroid-related medical conditions with reduced folates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1320776B1 (it) * 2000-08-07 2003-12-10 Giampiero Valletta Composizione farmaceutica a base di un'associazione vitaminica per laterapia delle cefalee primarie
WO2012171065A1 (en) * 2011-06-17 2012-12-20 Esra Ogru Treatment of allan-herndon-dudley syndrome with 3,5-diiodothyropropionic acid (ditpa).
US10640748B2 (en) * 2014-12-24 2020-05-05 Neuorphan Pty Ltd Oligodendroglial cell culturing methods and in methods for treating neurodegenerative disorders by using thyroid hormones or analogues
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030352A1 (en) * 1999-10-28 2001-05-03 Cary Pharmaceuticals Inc. High dose folic acid for the treatment of hyperhomocysteinemia
US20110008464A1 (en) * 2009-07-10 2011-01-13 Scott Iii Linzy O Methods and compositions for treating thyroid-related medical conditions with reduced folates
CN102639009A (zh) * 2009-07-10 2012-08-15 林齐·O·斯科特三世 用于以还原叶酸治疗甲状腺相关医学病症的方法和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAE YOUNG LEE等: "Overcoming Monocarboxylate Transporter 8 (MCT8)-Deficiency to Promote Human Oligodendrocyte Differentiation and Myelination", EBIOMEDICINE, vol. 25, 1 November 2017 (2017-11-01), pages 122 - 135, XP055475786, DOI: 10.1016/j.ebiom.2017.10.016 *
杜育霖: "血清维生素B12、叶酸与多发性硬化相关性的研究进展", 中国临床实用医学, vol. 10, no. 3, 25 July 2019 (2019-07-25), pages 70 - 73 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121910745A (zh) * 2026-03-23 2026-04-24 暨南大学 N-乙酰神经氨酸在制备治疗甲基苯丙胺成瘾的药物中的应用
CN121910745B (zh) * 2026-03-23 2026-05-26 暨南大学 N-乙酰神经氨酸在制备治疗甲基苯丙胺成瘾的药物中的应用

Also Published As

Publication number Publication date
EP4138809A1 (en) 2023-03-01
MX2022013140A (es) 2022-11-16
EP4138809A4 (en) 2024-05-01
CA3175608A1 (en) 2021-10-28
US20230149410A1 (en) 2023-05-18
KR20230015906A (ko) 2023-01-31
AU2021260956A1 (en) 2022-11-17
IL297453A (en) 2022-12-01
PH12022553118A1 (en) 2023-04-03
WO2021216896A1 (en) 2021-10-28
BR112022021420A2 (pt) 2022-12-27
JP2023522956A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
JP2023522956A (ja) 甲状腺ホルモンと関連する病態の治療
US20240325430A1 (en) Multiple folate formulation and use thereof
JP2023068107A (ja) 甲状腺関連の医学的状態を還元葉酸によって処置するための方法および組成物
US20080206360A1 (en) Folate based migraine treatment
HK40091636A (en) Treatment of conditions associated with thyroid hormone
US20240058346A1 (en) Treatment of Conditions Associated With Decreased Folate in Cerebral Spinal Fluid
AU2017204233B2 (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
Camfield in the Treatment of Anxiety
HK1174798B (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40091636

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230404

WD01 Invention patent application deemed withdrawn after publication